Catalyst Calendar

Wed, Sep 2, 2026

1 updates

8:00 AM

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026

solidbio.com

Thu, Aug 6, 2026

1 updates

SLDB

4:08 PM

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 - - Solid expects to meet with the FDA in late Q4 2026 to discuss the SGT-003 data package and to seek guidance on a potential

Trial Start • Phase 3Trial initiation Thu, May 7, 2026solidbio.com